Active Biotech AB has presented results from pre-clinical studies at the 99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, USA.
LUND, SWEDEN | April 15, 2008 | Active Biotech AB (OMX Nordic:ACTI) has presented results from pre-clinical studies at the 99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, USA.
The technology behind the project ANYARA; Tumor Targeted Superantigens; "TTS", was studied and evaluated in combination with a standard chemotherapeutic agent, Taxotere® (docetaxel). The complete poster "Combining tumor-targeted superantigens with docetaxel results in synergistic anti-tumor effects in B16 tumor bearing mice" can be viewed at www.activebiotech.com.
Combining TTS and Taxotere® significantly improved anti-tumor activity compared to the respective mono therapy. Furthermore, combining TTS and Taxotere® synergistically prolonged long-term survival in tumor bearing mice.
In conclusion, the results of the study demonstrate that TTS therapy is suitable for combination treatment agents such as Taxotere®, and suggest a significant potential for such a combination in human cancer therapy.
The drug candidate ANYARA, using the TTS technology, is currently in pivotal Phase II/III clinical trials for Renal Cell Cancer and an interim analysis is planned for mid 2008.
ANYARA has also been tested in Phase I clinical trials with Taxotere® 1) in patients with Non Small Cell Lung Cancer (NSCLC). This trial demonstrated that the combination is safe and indicated anti-tumor activity.
About ANYARA
Active Biotech’s ANYARA project develops a drug for use in cancer targeted therapy, primarily for the treatment of renal cell cancer. A Phase II/III study is ongoing since the end of 2006. It is a randomized study of ANYARA in combination with interferon-alpha, compared with only interferon-alpha, in patients with advanced renal cell cancer.
The primary clinical effect parameter for this study is survival and it will include approximately 500 patients at 45 clinics in Europe. Expected survival with conventional treatment for these patients is 10-15 months and the length of the study will depend on the patients’ disease progression. An interim analysis is scheduled for mid 2008.
About Active Biotech
Active Biotech AB (OMX Nordic:ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA.
SOURCE: Active Biotech AB
Post Views: 57
Active Biotech AB has presented results from pre-clinical studies at the 99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, USA.
LUND, SWEDEN | April 15, 2008 | Active Biotech AB (OMX Nordic:ACTI) has presented results from pre-clinical studies at the 99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, USA.
The technology behind the project ANYARA; Tumor Targeted Superantigens; "TTS", was studied and evaluated in combination with a standard chemotherapeutic agent, Taxotere® (docetaxel). The complete poster "Combining tumor-targeted superantigens with docetaxel results in synergistic anti-tumor effects in B16 tumor bearing mice" can be viewed at www.activebiotech.com.
Combining TTS and Taxotere® significantly improved anti-tumor activity compared to the respective mono therapy. Furthermore, combining TTS and Taxotere® synergistically prolonged long-term survival in tumor bearing mice.
In conclusion, the results of the study demonstrate that TTS therapy is suitable for combination treatment agents such as Taxotere®, and suggest a significant potential for such a combination in human cancer therapy.
The drug candidate ANYARA, using the TTS technology, is currently in pivotal Phase II/III clinical trials for Renal Cell Cancer and an interim analysis is planned for mid 2008.
ANYARA has also been tested in Phase I clinical trials with Taxotere® 1) in patients with Non Small Cell Lung Cancer (NSCLC). This trial demonstrated that the combination is safe and indicated anti-tumor activity.
About ANYARA
Active Biotech’s ANYARA project develops a drug for use in cancer targeted therapy, primarily for the treatment of renal cell cancer. A Phase II/III study is ongoing since the end of 2006. It is a randomized study of ANYARA in combination with interferon-alpha, compared with only interferon-alpha, in patients with advanced renal cell cancer.
The primary clinical effect parameter for this study is survival and it will include approximately 500 patients at 45 clinics in Europe. Expected survival with conventional treatment for these patients is 10-15 months and the length of the study will depend on the patients’ disease progression. An interim analysis is scheduled for mid 2008.
About Active Biotech
Active Biotech AB (OMX Nordic:ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA.
SOURCE: Active Biotech AB
Post Views: 57
